Pfizer (PFE) has dominated headlines this year with its failed Allergan (AGN) merger and its Anacor Pharmaceuticals (ANAC) purchase. Nevertheless, Tom Forester, portfolio manager for the Forester Value Fund (FVALX) , said there is more to the drug giant's stock higher than deal-making. 'Pfizer is not all about acquisitions, it has a great pipeline,' said Forester. 'And it has easier comps on the horizon because it has been over a year since a number of its previous blockbuster drugs came off patent.' Last week Pfizer, up 6.3 percent thus far in 2016, announced its plan to spend $5.2 billion on Anacor Pharmaceuticals to build up its inflammation and immunology business. The deal gives Pfizer access to Crisaborole, an anti-inflammatory drug currently under U.S. Food and Drug Administration review for the treatment of mild-to-moderate atopic dermatitis, or eczema. The Forester Value Fund is down 60 basis points thus far in 2016, according to Morningstar. The $98 million fund has returned an average of 2% annually over the past decade, putting it in the 91% percentile in Morningstar's long/short equity category.

More from Video

What's Behind the Retail Sector's Fall From Grace? NYSE Trader Weighs in

What's Behind the Retail Sector's Fall From Grace? NYSE Trader Weighs in

Jim Cramer Likes Secular Growers

Jim Cramer Likes Secular Growers

In the Shadow of Bankruptcy: Distressed Investing Opportunity

In the Shadow of Bankruptcy: Distressed Investing Opportunity

$1,320 Gold May Be In The Cards

$1,320 Gold May Be In The Cards

CES 2019: The Future Is Here and it's a Walking Car

CES 2019: The Future Is Here and it's a Walking Car